Clinical trial
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With…
NCT00375310 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00375310 |
|---|---|
| Title | Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer |
| Official title | Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Amgen Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer, Adenocarcinoma of the Pancreas |
| Intervention type | Drug, Procedure |
| Interventions | Gemcitabine, Sorafenib, Radiotherapy |
| Enrollment | 27 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2010 |
| Completion | Nov 1, 2014 |
| First posted | Sep 12, 2006 |
| Last update posted | Feb 29, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: